Ready-Made immune cells take on lymphoma and leukemia in first human trial
NCT ID NCT07518329
First seen Apr 16, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This early-phase study tests ALA-101, a pre-made cell therapy that targets CD19 on cancer cells, in adults with certain types of non-Hodgkin lymphoma or leukemia. The main goal is to check safety and find the best dose. About 46 participants will receive the treatment and be monitored for side effects and signs that the cancer shrinks or disappears.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA (NHL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epworth HealthCare
Richmond, Victoria, 3121, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.